Improving diagnosis of infectious diseases
Pictor’s diagnostic products address the need for improved diagnoses of infectious diseases, a global problem brought to everyone’s attention by Covid19. A threat, which by fortune of geography and prompt political and public health actions, New Zealand has managed to keep in check and, in a global sense, effectively avoid.
Pictor’s diagnostic products address the need for improved diagnoses of infectious diseases,
a global problem brought to everyone’s attention by Covid19. A threat,
which by fortune of geography and prompt political and public health
actions, New Zealand has managed to keep in check and, in a global
sense, effectively avoid.
This has brought worldwide attention to Pictor’s products, further
increasing New Zealand’s reputation as safe haven guarding us from many
leading infectious diseases. These figures are enormous and include 248
million people suffering from chronic hepatitis B, 536 million from
herpes, and 390 million people who are infected with dengue each year.
And in addition to Covid19, infections from other mosquito borne disease
such as Yellow Fever and Zika are also a growing threat.
As a result of this demand, Pictor is now partnering with Timaru based
South Pacific Sera to expand its manufacturing capacity so that it can
meet the expected demand for its COVID-19 IgG antibody assay and also
its Mycoplasma bovis assay. Both Pictor and South Pacific Sera will be
using the latest microarray technology to manufacture these diagnostic
assays.
Subscriptions are still being received for the current Offer
seeking $2.5 million by the issue of preferred shares in the Company
and with 75% already subscribed it is expected to close before the end
of the year.
If you’re interested please reply promptly to this email for a copy of the IM and include your phone number.
..................................................................................................
Any reference above to investment is not an offer of financial
products that requires disclosure under the Financial Markets Conduct
Act 2013 (Act) and is available only to wholesale investors as defined
by that Act. It is intended for distribution only to selected people to
whom, under the relevant laws, it can be lawfully distributed. It cannot
be distributed in any other jurisdiction, or to any other people. It is
not an offer or solicitations in any jurisdiction in which such offers
or solicitations are not authorised, or in which the person making such
offers or solicitations are not qualified to do so, or to any person to
whom it is unlawful to make such offers or solicitations. Any
representation to the contrary would be unlawful. No action has been
taken by any person that would permit a public offering in any
jurisdiction where action for that purpose would be required.
Cheers
John Paine B.Sc., Dip BIA
TBK Capital Limited
Level 10, 120 Albert Street
Auckland 1010, New Zealand
Phone +64 9 307 3257
Mobile +64 21 902 901
Email john.paine@tbkcapital.co.nz
For more information, please click the contact button below to send us a message.
⇑ back to top